A Phase 2 interventional study of capecitabine (Xeloda®) and docetaxel (Taxotere®) in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 94 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-10.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.
Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 23rd largest by enrollment of the 227 interventional ones that give a count, is one of 14 that started in 2003, is one of 121 in phase 2, and was the 16th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Biostar Pharma, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 146 · Phase 3 55 · Phase 4 6
First in 1998; this study’s year is marked. 14 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 470 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 227 interventional studies. Of the 149 that completed or were terminated, 54 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 233 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 27 under way, 13 of them phase 3. Of 194 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 35th largest by enrollment of the 170 interventional ones that give a count, is one of 3 that started in 2003, is one of 65 in phase 2, and was the 7th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing capecitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT06764940Biostar Pharma, Inc.A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | 2027-01-15 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
| NCT06247995Novartis PharmaceuticalsA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | 2027-04-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 233 studies testing capecitabine in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure of chemotherapy with an anthracycline. Patients were randomized to receive either 1250 mg/m\^2 or 825 mg/m\^2 orally twice a day (po bid) on days 1-14 of each 3 week cycle, in combination with Taxotere® 75 mg/m2 intravenous (iv) on day 1 of each 3 week cycle. The anticipated time on study treatment was until disease progression and the target sample size was 440 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1250 mg/m\^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m\^2 intravenous on day 1 of each 3 week cycle.
Drug: capecitabine (Xeloda®) · Drug: docetaxel (Taxotere®)
825 mg/m\^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m\^2 intravenous on day 1 of each 3 week cycle.
Drug: capecitabine (Xeloda®) · Drug: docetaxel (Taxotere®)
825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
Also known as: Xeloda®
75 mg/m\^2 intravenous on day 1 of each 3 week cycle
Also known as: Taxotere®
Time to Progression of Disease or Death
Progression Free Survival was defined as the time from the date of randomization to the day of documented disease progression or death due to any cause.
Time frame: Event driven (after 350 events). Median observation time was approximately 16 months.
Percentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR)
According to Response Evaluation Criteria in Solid Tumors (RECIST) criteria: CR is defined as the disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the nadir sum LD.
Time frame: Until Progressive Disease (PD) or end of primary study treatment (up to 16 cycles) plus 28 days.
Time to Overall Response
For patients with Best Overall Response being Complete Response (CR) or Partial Response (PR), time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR were met. The percentage of participants with overall response within the given time ranges in each of the categories: Weeks 1-6, 7-12, 13-18, 19-24, 25-30, 31-36, and 43-48 are reported.
Time frame: Until PD or end of primary study treatment (up to 16 cycles) plus 28 days.
Duration of Overall Response
Duration of overall response was measured from the time that measurement criteria were first met for Complete Response or Partial Response until the first date that progressive disease or death was documented.
Time frame: Until PD or death. Median duration of response was approximately 7 months.
Time to Treatment Failure
The time to treatment failure was the time from the date of randomization to the first occurrence of any of the following events: * adverse events * insufficient therapeutic response (disease progression) * death * failure to return * refusing treatment/being unwilling to cooperate * withdrawing consent.
Time frame: Until premature withdrawal or end of primary study treatment (up to 16 cycles).
Overall Survival
Overall Survival was measured as the time from the date of randomization to the date of death.
Time frame: Throughout the study. Median observation time was approximately 16 months.
Number of Participants With Adverse Events and Serious Adverse Events
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Additional information about Adverse Events can be found in the Adverse Event Section.
Time frame: First study drug intake until last study drug intake plus 28 days
| Milestone | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Started | 235 | 235 |
| Received study drug | 231 | 234 |
| Safety population: actual dose received | 217 | 248 |
| Completed | 34 | 31 |
| Not completed | 201 | 204 |
| Withdrew: Adverse event | 30 | 32 |
| Withdrew: Death | 7 | 3 |
| Withdrew: Insufficient therapeutic response | 112 | 128 |
| Withdrew: Violation of selection criteria at entry | 3 | 1 |
| Withdrew: Other protocol violation | 0 | 1 |
| Withdrew: Refused treatment | 29 | 21 |
| Withdrew: Failure to return | 5 | 5 |
| Withdrew: Other | 15 | 13 |
Progression Free Survival was defined as the time from the date of randomization to the day of documented disease progression or death due to any cause.
| Months | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Time to Progression of Disease or Death | 7.9 (6.9 to 8.5) | 5.8 (4.9 to 7.1) |
According to Response Evaluation Criteria in Solid Tumors (RECIST) criteria: CR is defined as the disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the nadir sum LD.
| Percentage of participants | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Percentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR) | 45.1 (38.6 to 51.7) | 37.4 (31.2 to 44.0) |
For patients with Best Overall Response being Complete Response (CR) or Partial Response (PR), time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR were met. The percentage of participants with overall response within the given time ranges in each of the categories: Weeks 1-6, 7-12, 13-18, 19-24, 25-30, 31-36, and 43-48 are reported.
| Percentage of participants | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Week 1-6 | 25 | 30 |
| Week 7-12 | 48 | 30 |
| Week 13-18 | 20 | 17 |
| Week 19-24 | 7 | 7 |
| Week 25-30 | 3 | 1 |
| Week 31-36 | 3 | 2 |
| Week 43-48 | 0 | 1 |
Duration of overall response was measured from the time that measurement criteria were first met for Complete Response or Partial Response until the first date that progressive disease or death was documented.
| Months | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Duration of Overall Response | 6.9 (6.1 to 8.6) | 6.9 (5.8 to 9.0) |
The time to treatment failure was the time from the date of randomization to the first occurrence of any of the following events: * adverse events * insufficient therapeutic response (disease progression) * death * failure to return * refusing treatment/being unwilling to cooperate * withdrawing consent.
| Months | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Time to Treatment Failure | 5.1 (4.2 to 5.8) | 4.6 (4.1 to 5.3) |
Overall Survival was measured as the time from the date of randomization to the date of death.
| Months | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Overall Survival | 16.4 (13.6 to 21.8) | 15.1 (12.9 to 17.7) |
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Additional information about Adverse Events can be found in the Adverse Event Section.
| Participants | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Adverse Events | 206 | 234 |
| Serious Adverse Events | 41 | 53 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1250 mg/m^2 Capecitabine + Docetaxel | — | 41/217 (18.9%) | 192/217 (88.5%) |
| 825 mg/m^2 Capecitabine + Docetaxel | — | 53/248 (21.4%) | 223/248 (89.9%) |
| Event | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 13/217 | 14/248 |
| NeutropeniaBlood and lymphatic system disorders | 6/217 | 4/248 |
| Stomatitis allGastrointestinal disorders | 5/217 | 0/248 |
| Palmar-Plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 3/217 | 1/248 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/217 | 3/248 |
| AstheniaGeneral disorders | 0/217 | 3/248 |
| LeukopeniaBlood and lymphatic system disorders | 2/217 | 0/248 |
| DiarrhoeaGastrointestinal disorders | 2/217 | 2/248 |
| VomitingGastrointestinal disorders | 2/217 | 2/248 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/217 | 1/248 |
| Event | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel |
|---|---|---|
| Palmar-Plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 102/217 | 104/248 |
| Stomatitis allGastrointestinal disorders | 87/217 | 88/248 |
| NeutropeniaBlood and lymphatic system disorders | 77/217 | 70/248 |
| AlopeciaSkin and subcutaneous tissue disorders | 74/217 | 82/248 |
| DiarrhoeaGastrointestinal disorders | 73/217 | 81/248 |
| FatigueGeneral disorders | 58/217 | 50/248 |
| NauseaGastrointestinal disorders | 45/217 | 58/248 |
| VomitingGastrointestinal disorders | 33/217 | 45/248 |
| PyrexiaGeneral disorders | 35/217 | 27/248 |
| Nail disorderSkin and subcutaneous tissue disorders | 26/217 | 38/248 |
| Age Continuous(years) | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel | Total |
|---|---|---|---|
| Mean | 50.9 (22 to 75) | 50.6 (28 to 75) | 50.75 (22 to 75) |
| Sex: Female, Male(Participants) | 1250 mg/m^2 Capecitabine + Docetaxel | 825 mg/m^2 Capecitabine + Docetaxel | Total |
|---|---|---|---|
| Female | 235 | 235 | 470 |
| Male | 0 | 0 | 0 |
The record gives a start of Jul 2003, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Docetaxel